Form 4: Enliven Therapeutics CEO Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics, Inc. President and CEO, Samuel Kintz, reported the sale of 7,500 shares of common stock for approximately $20.05 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO, and Director of Enliven Therapeutics, Inc. (ELVN), reported a transaction on June 3, 2025.
• He sold 7,500 shares of Enliven Therapeutics Common Stock.
• The shares were sold at a weighted average price of $20.0469 per share, with individual trades ranging from $20.00 to $20.11.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on November 15, 2024.
• Following this transaction, Samuel Kintz beneficially owns 965,392 shares of common stock, including shares held indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: Neutral. The document reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is a common practice for personal financial management and does not inherently signal positive or negative company performance or a change in outlook.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction for personal financial management rather than a reaction to immediate company news or performance.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Risks

• Potential for negative market perception from insider selling, which could lead to minor downward pressure on the stock price, although mitigated by the 10b5-1 plan disclosure.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance, strategic direction, or operational outlook. It solely reports an insider transaction.

Management Comments

• "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."
• "This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price."
• "The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are common and can occur for various personal financial planning reasons, especially when executed under pre-arranged 10b5-1 plans, which are designed to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some might view it as a minor negative signal, while others will recognize it as a planned personal financial move, especially given the 10b5-1 plan.

Next Steps

• The document does not specify any future actions, events, or milestones for the company. It is a historical report of a completed transaction.

Key Dates

Recommendation

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Sale, Samuel Kintz, Rule 10b5-1, Biotechnology, Pharmaceuticals